News Releases

resTORbio Presents Additional Phase 2b Data at the American Thoracic Society International Conference for RTB101 as a Potential Immunotherapy to Reduce the Incidence of Respiratory Tract Infections in Patients 65 Years of Age and Older with Asthma
RTB101 10 mg once daily was observed to reduce the rate of laboratory-confirmed Respiratory Tract Infections (RTIs) by 78.7% (p=0.001) and the rate of all RTIs (with or without laboratory confirmation) by 66.4% (p=0.003) as compared to placebo among Phase 2b participants 65 years of age and older
May 20, 2019
resTORbio to Participate at Upcoming Investor Conferences in May
BOSTON , May 01, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases, today announced that company management will participate in two investor
May 01, 2019
resTORbio, Inc. Announces Closing Public Offering of Common Stock
BOSTON , March 22, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (“resTORbio” or the “Company”) (Nasdaq:TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat age-related diseases, today announced the closing of its
Mar 22, 2019
resTORbio, Inc. Announces Proposed Public Offering of Common Stock
BOSTON , March 18, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. ("resTORbio" or the "Company") (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat age-related diseases, today announced that it has commenced an
Mar 18, 2019